Novel Azaheterocyclic Compounds as Kinase Inhibitors

Compounds of the formula I

• in which
• R1 denotes H, A, Ar, Ar-A or A-Ar,
• A denotes unbranched, branched or cyclic alkyl having 1-14 C atoms, in which one or two CH2 groups may be replaced by an O or S atom and/or by an NH, NA, CONH, NHCO or —CH═CH— group and/or, in addition, 1-7 H atoms may be replaced by HaI, and in which one or two CH3 groups may be replaced by NH2, NAH, NA2, NHCOOA, NHCONHA, NHCONHAr, or CN,
• Ar denotes a mono- or bicyclic aromatic homo- or heterocycle having 1 to 4 N, O and/or S atoms and 5 to 10 skeleton atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, HaI, A, OH, OA, NH2, NHA, NA2, NO2, CN, OCN, SCN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHCONH2, NHSO2A, CHO, COA, SO2NH2 and/or S(O)gA,
• Ar-A denotes aryl-alkyl
• A-Ar denotes alkyl-aryl
• HaI denotes F, Cl, Br or I,
• X denotes CH or N, where one group X in each compound of the formula I is N and two groups X are CH,
• Y denotes CH2 or a saturated bond,
• Z denotes CH or N, where at most two groups Z in each compound of the formula I are NH and preferably one or no group Z is NH,
• R2′, R2″, R2′″, R″″ each, independently of one another, denote H, HaI, OH, CN, NH2, unbranched or branched alkyl having 1-4, 5 or 6 C atoms, in which one CH2 group may be replaced by an O or S atom and/or by an NH, NA, CONH, NHCO or —CH═CH— group and/or, in addition, 1-4 H atoms may be replaced by HaI, and in which one CH3 group may be replaced by NH2, NAH, NA2, CN or Ar,
• R3 denotes H, A or Ar-A,
• g denotes 0, 1 or 2 and
• denotes a single or double bond,
• and pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.